Notable Labs, Ltd. Price & Performance (NTBL)

Biocon Biologics has finalized a settlement and licensing agreement with Regeneron, allowing the launch of its aflibercept biosimilar, Yesafili, in the US by late 2026. The deal resolves ongoing litigation and positions Biocon among the first to offer an interchangeable Eylea alternative, expanding its ophthalmology portfolio.12

Silexion Therapeutics is preparing for toxicology studies of its siRNA candidate, SIL204, targeting locally advanced pancreatic cancer, with regulatory submissions for Phase 2/3 trials expected in early 2026. The company is also exploring partnerships to expand its oncology pipeline, aiming for broader clinical and commercial impact.34

Vascular Biogenics Ltd. (VBLT) continues to be rated as a 'hold' by analysts, reflecting mixed sentiment and low trading liquidity. The stock, delisted from NASDAQ, has seen little recent movement, with the latest price at $0.156 per share and a market cap of $12.1 million.567